Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers.

Lee JW, Berkowitz Z, Saraiya M.

Obstet Gynecol. 2011 Jul;118(1):4-13. doi: 10.1097/AOG.0b013e3182210034.

PMID:
21691157
2.

Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP).

Saraiya M, Irwin KL, Carlin L, Chen X, Jain N, Benard V, Montano DE.

Cancer. 2007 Sep 1;110(5):1024-32.

3.

Abuses in human papillomavirus DNA testing.

Castle PE.

Obstet Gynecol. 2011 Jul;118(1):1-3. doi: 10.1097/AOG.0b013e3182228630. No abstract available. Erratum in: Obstet Gynecol. 2011 Nov;118(5):1184.

PMID:
21691156
4.

Cervical cancer screening, abnormal cytology management, and counseling practices in the United States.

Irwin K, Montaño D, Kasprzyk D, Carlin L, Freeman C, Barnes R, Jain N, Christian J, Wolters C.

Obstet Gynecol. 2006 Aug;108(2):397-409.

PMID:
16880312
6.

Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?

Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V.

Arch Intern Med. 2010 Jun 14;170(11):977-85. doi: 10.1001/archinternmed.2010.134.

PMID:
20548011
7.

Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.

Ciotti M, Sesti F, Paba P, Benedetto A, Patrizi L, Criscuolo A, Piccione E, Branca M, Syrjänen K, Favalli C.

Eur J Gynaecol Oncol. 2004;25(5):577-84.

PMID:
15493169
8.

Human papillomavirus vaccine practices in the USA: do primary care providers use sexual history and cervical cancer screening results to make HPV vaccine recommendations?

Kepka D, Berkowitz Z, Yabroff KR, Roland K, Saraiya M.

Sex Transm Infect. 2012 Oct;88(6):433-5. Epub 2012 Apr 21.

PMID:
22522751
9.

Human papillomavirus and Papanicolaou tests screening interval recommendations in the United States.

Roland KB, Soman A, Benard VB, Saraiya M.

Am J Obstet Gynecol. 2011 Nov;205(5):447.e1-8. doi: 10.1016/j.ajog.2011.06.001. Epub 2011 Jun 12.

PMID:
21840492
10.
12.

Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005.

Datta SD, Koutsky LA, Ratelle S, Unger ER, Shlay J, McClain T, Weaver B, Kerndt P, Zenilman J, Hagensee M, Suhr CJ, Weinstock H.

Ann Intern Med. 2008 Apr 1;148(7):493-500.

PMID:
18378945
13.

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.

Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J.

J Natl Cancer Inst. 2004 Feb 18;96(4):280-93.

PMID:
14970277
14.

Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States.

Baseman JG, Kulasingam SL, Harris TG, Hughes JP, Kiviat NB, Mao C, Koutsky LA.

Am J Obstet Gynecol. 2008 Jul;199(1):26.e1-8. doi: 10.1016/j.ajog.2007.11.051. Epub 2008 Mar 7.

PMID:
18313636
16.

Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.

Tiews S, Steinberg W, Schneider W, Hanrath C.

J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1.

PMID:
20129068
17.

Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.

Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M.

J Natl Cancer Inst. 2003 Jan 1;95(1):46-52.

PMID:
12509400
18.

Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Johansson B, Forslund O, Hansson BG, Rylander E, Dillner J.

N Engl J Med. 2007 Oct 18;357(16):1589-97. Erratum in: N Engl J Med. 2008 Oct 9;359(15):1637. Johansson, Bo [added].

19.

Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.

Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR, Rush BB, Demuth F, Schiffman M.

Cancer. 2002 Nov 15;95(10):2145-51.

20.

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, Ratnam S, Coutlée F, Franco EL; Canadian Cervical Cancer Screening Trial Study Group.

N Engl J Med. 2007 Oct 18;357(16):1579-88.

Supplemental Content

Support Center